The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.
Daniel C. Chung, DO, MA
Advertisement
Chung is Chief Medical Officer of Beacon Therapeutics
Articles by Daniel C. Chung, DO, MA
Advertisement
Latest Updated Articles
Navigating the maze: Establishing novel end points for IRD trialsPublished: October 1st 2025 | Updated:
